CD8A and cancer: Based on the observation that higher frequencies of pre-existing effector memory T cells were detectable in the blood of responders to the combination of CDK4/6 inhibitors and CPI (Egelston et al., 2021), early treatment with CDK4/6 inhibitors to establish a memory CD8+ T cell pool followed by the CPI administration may represent a promising therapeutic strategy for cancer patients.